SHENNONG(神农):一项在确诊为动脉硬化性心血管疾病的中国患者中评估依洛尤单抗联合标准治疗与单用标准治疗相比对主要心血管事件的疗效的真实世界、前瞻性、观察性研究
根据当地临床实践,在应用标准治疗(SOC)确诊为ASCVD的患者中进行一项疗效对比研究,旨在评估依洛尤单抗联合标准治疗(SOC)与单用标准治疗相比,对CV死亡、MI、卒中、因不稳定型心绞痛住院治疗或冠状血管重建等风险的真实世界疗效,以先发生者为准。
Experiences of Palliative Nephrology and Pre-Dialysis Clinics (EXPAND): survival, symptom control and quality of life of patients not planned for dialysis who are receiving renal supportive care.
An open label phase 2 study of doxorubicin and cyclophosphamide followed by paclitaxel (AC-T) delivered every 14 days with pegfilgrastim and darbepoetin alfa support for the adjuvant treatment of women with breast cancer
100 项与 Amgen Australia Pty Ltd. 相关的临床结果
0 项与 Amgen Australia Pty Ltd. 相关的专利(医药)
100 项与 Amgen Australia Pty Ltd. 相关的药物交易
100 项与 Amgen Australia Pty Ltd. 相关的转化医学